| 000 | 02673nam a22004455i 4500 | ||
|---|---|---|---|
| 001 | 978-1-4419-7073-2 | ||
| 003 | DE-He213 | ||
| 005 | 20140220083722.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 101109s2011 xxu| s |||| 0|eng d | ||
| 020 |
_a9781441970732 _9978-1-4419-7073-2 |
||
| 024 | 7 |
_a10.1007/978-1-4419-7073-2 _2doi |
|
| 050 | 4 | _aRC254-282 | |
| 072 | 7 |
_aMJCL _2bicssc |
|
| 072 | 7 |
_aMED062000 _2bisacsh |
|
| 082 | 0 | 4 |
_a616.994 _223 |
| 100 | 1 |
_aLyman, Gary H. _eeditor. |
|
| 245 | 1 | 0 |
_aHematopoietic Growth Factors in Oncology _h[electronic resource] / _cedited by Gary H. Lyman, David C. Dale. |
| 250 | _a1. | ||
| 264 | 1 |
_aBoston, MA : _bSpringer US, _c2011. |
|
| 300 |
_aXV, 433 p. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 |
_aCancer Treatment and Research, _x0927-3042 ; _v157 |
|
| 520 | _aNo area of cancer supportive care better illustrates the advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of hematopoietic growth factors. Myelosuppressive agents, with their potential hematopoietic toxicities, remain the mainstay of systemic treatment for both metastatic and early stage cancer. Hematopoietic Growth Factors in Oncology reviews and integrates the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents, each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. "Hematopoietic growth factors have revolutionized the treatment of patients with a spectrum of cancers and benign bone marrow disorders. This text addresses the mechanism of action and clinical impact of these cytokines. Leading investigators in the field provide and update of current state of knowledge and future challenges." – Steven T. Rosen, M.D. Series Editor | ||
| 650 | 0 | _aMedicine. | |
| 650 | 0 | _aOncology. | |
| 650 | 1 | 4 | _aMedicine & Public Health. |
| 650 | 2 | 4 | _aOncology. |
| 700 | 1 |
_aDale, David C. _eeditor. |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9781441970725 |
| 830 | 0 |
_aCancer Treatment and Research, _x0927-3042 ; _v157 |
|
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-1-4419-7073-2 |
| 912 | _aZDB-2-SME | ||
| 999 |
_c105684 _d105684 |
||